Please Wait
Applying Filters...
menu
    • menu
    Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Ever Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances, suspensions, etc.

    Virtual Booth

    Contact Supplier

    Topscience Biotech specializes in R&D, production, and sales of Sodium Hyaluronate, focusing on Medical and Pharmaceutical Grade HA.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Menu

    Caplacizumab

    ACTIVE PHARMA INGREDIENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Ablynx NV's Cablivi (caplacizumab) Receives Suppl Approval in the U.S.
    Ablynx NV's Cablivi (caplacizumab) Receives Suppl Approval in the U.S.

    11 Apr 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761112

    FDA
    11 Apr 2024
    Share Share
    Cablivi's Biologic Ablynx (Caplacizumab) Receives Approval in the U.S.
    Cablivi's Biologic Ablynx (Caplacizumab) Receives Approval in the U.S.

    23 Feb 2022

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761112

    FDA
    23 Feb 2022
    Share Share
    NICE green light for Cablivi in rare blood-clotting disorder
    NICE green light for Cablivi in rare blood-clotting disorder

    13 Nov 2020

    // Lucy Parsons PHARMATIMES

    http://www.pharmatimes.com/news/nice_green_light_for_cablivi_in_rare_blood-clotting_disorder_1356888

    Lucy Parsons PHARMATIMES
    13 Nov 2020
    Share Share
    NICE rejects Sanofi's Cablivi in draft guidelines
    NICE rejects Sanofi's Cablivi in draft guidelines

    13 Jun 2020

    // Selina McKee PHARMATIMES

    http://www.pharmatimes.com/news/nice_rejects_sanofis_cablivi_in_draft_guidelines_1342109

    Selina McKee PHARMATIMES
    13 Jun 2020
    Share Share
    Cablivi® approved by Health Canada for adults living with acquired (aTTP)
    Cablivi® approved by Health Canada for adults living with acquired (aTTP)

    02 Mar 2020

    // NEWSWIRE

    https://www.newswire.ca/news-releases/cablivi-r-caplacizumab-approved-by-health-canada-for-adults-living-with-acquired-thrombotic-thrombocytopenic-purpura-attp--808888426.html

    NEWSWIRE
    02 Mar 2020
    Share Share
    Innovative treatment Cablivi (caplacizumab-yhdp) granted new technology payment
    Innovative treatment Cablivi (caplacizumab-yhdp) granted new technology payment

    10 Oct 2019

    // PRESS

    http://www.news.sanofi.us/2019-10-09-Innovative-treatment-Cablivi-caplacizumab-yhdp-granted-new-technology-payment-NTAP-for-Medicare-payment

    PRESS
    10 Oct 2019
    Share Share